| Conmana (icotinib) / Betta Pharma |
Spring-Lung 6, ChiCTR-IIR-17012197: A phase II, open-label, randomised controlled trial of icotinib with and without metronomic oral vinorelbine as first-line therapy in patients with EGFR mutation-positive advanced nonsquamous non–small-cell lung cancer. |
|
|
| Not yet recruiting | 2 | 120 | | Icotinib 125mg orally(PO) tid + vinorelbine 40mg po three times weekly (Monday-Wednesday-Friday) continuously until disease progression, unacceptable toxicity or patient refusal. ;Icotinib 125mg orally(PO) tid continuously until disease progression, unacceptable toxicity or patient refusal. | Shandong Cancer Hospital and Institute; Shandong Cancer Hospital and Institute, The 13th five-year major new-drug-initiative project | non-small cell lung cancer | | | | |
NCT02726568: High Dose Icotinib With Sequential SRS For NSCLC Patients Harboring EGFR Mutation With Brain Metastases |
|
|
| Recruiting | 2 | 30 | RoW | Icotinib, SRS | Betta Pharmaceuticals Co., Ltd. | Non-small Cell Lung Cancer, Brain Metastases | 12/21 | 12/22 | | |
GASTO-1031, ChiCTR-IIR-17012741: Phase Il Study of Apatinib Combined with Icotinib Versus Icotinib alone as First-Line Chemotherapy for Patients of Advanced Stage of non squamous NSCLC with EGFR gene mutantion |
|
|
| Not yet recruiting | 2 | 120 | | Take Apatinib (250mg qd, after meals) + Icotinib (125mg, tid, before meals) orally ;Take Icotinib (125mg, tid, before meals) orally | The Affiliated Hospital Guangdong Medical University; Affiliated Hospital Guangdong Medical University, Guangdong Medical University Affiliated Hospital Clinical Research Project | Non-Small Cell Lung Cancer | | | | |
NCT03396185: Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung Cancer |
|
|
| Recruiting | 2 | 30 | RoW | Icotinib, Conmana | Betta Pharmaceuticals Co., Ltd. | EGFR Gene Mutation, Non Small Cell Lung Cancer Stage IIIA, Non Small Cell Lung Cancer Stage IIIB | 02/22 | 02/23 | | |
NCT03349203: Icotinib as Neoadjuvant and Adjuvant Therapy in EGFR-mutant Stage IIIB or Oligometastasis Non-small Cell Lung Cancer |
|
|
| Recruiting | 2 | 60 | RoW | Icotinib, Conmana | Betta Pharmaceuticals Co., Ltd. | EGF-R Positive Non-Small Cell Lung Cancer | 02/22 | 12/23 | | |
NCT03749213: Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer |
|
|
| Recruiting | 2 | 36 | RoW | Icotinib, Conmana | Betta Pharmaceuticals Co., Ltd. | EGF-R Positive Non-Small Cell Lung Cancer | 02/22 | 12/24 | | |
NCT02820116: The Role of Icotinib in the Perioperative Treatment of IIIA - IIIB NSCLC Patients With EGFR Mutation |
|
|
| Recruiting | 2 | 67 | RoW | Icotinib, Conmana | Beijing Haidian Hospital, Peking University People's Hospital, 307 Hospital of PLA, 309th Hospital of Chinese People's Liberation Army | Non-small Cell Lung Cancer(NSCLC) | 04/23 | 04/23 | | |
NCT06186804: A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD) |
|
|
| Recruiting | 2 | 64 | RoW | ABSK021 | Abbisko Therapeutics Co, Ltd | cGvHD | 10/26 | 12/26 | | |
NCT05263947: Bevacizumab Combined With Double Dose Icotinib in Patients With EGFR Exon 21-L858R Mutation |
|
|
| Recruiting | 2 | 35 | RoW | Bevacizumab and Icotinib, Combined treatment group | Tianjin Medical University Cancer Institute and Hospital | Carcinoma, Non-Small-Cell Lung, Bevacizumab, EGF-R Positive Non-Small Cell Lung Cancer, Tyrosine Kinase Inhibitor | 10/23 | 12/23 | | |
NCT05007938: Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung Cancer |
|
|
| Recruiting | 2 | 30 | RoW | Icotinib, Conmana, Befotertinib, D-0316 | Betta Pharmaceuticals Co., Ltd., The First Affiliated Hospital of Xiamen University | Non-Small Cell Lung Cancer | 12/23 | 12/24 | | |
NeoIpower, NCT05104788: A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer |
|
|
| Recruiting | 2 | 27 | RoW | Icotinib, Cisplatin, Carboplatin, Pemetrexed | Beijing Cancer Hospital | Non-Small Cell Lung Cancer | 03/24 | 12/26 | | |
NCT05132985: Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung Adenocarcinoma |
|
|
| Not yet recruiting | 2 | 45 | RoW | Icotinib, Conmana, Cisplatin, Carboplatin, Pemetrexed | Liaoning Tumor Hospital & Institute | NSCLC, EGF-R Positive Non-Small Cell Lung Cancer | 07/24 | 01/28 | | |
ChiCTR2200060151: Furonertinib mesylate with Icotinib as first line treatment in locally advanced or metastatic non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) mutation positive: a single-arm single-center phase II study |
|
|
| Recruiting | 2 | 40 | | Furmonertinib+Icotinib | Affiliated Hospital of Guangdong Medical University; Affiliated Hospital of Guangdong Medical University, Xisike-Allist Lung Cancer Target Therapy Research Foundation; Shanghai Allist Pharmaceuticals Co., Ltd.; Betta Pharmaceuticals Co., Ltd. | Lung cancer | | | | |
NCT05514314: A Multicenter Prospective Study to Assess the Effects of Adjuvant Icotinib in EGFRm Stage I NSCLC With High-risk of Disease Recurrence After Complete Resection |
|
|
| Not yet recruiting | 2 | 90 | NA | Icotinib | Wu Nan | Non-Small Cell Lung Cancer | 09/24 | 06/25 | | |
| Recruiting | 2 | 128 | RoW | Icotinib, BPI-2009, Conmana | Sun Yat-sen University | Lung Neoplasms, Squamous Cell Lung Cancer, Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Large Cell Lung Cancer, Bronchial Neoplasms, Stage IB Non-small Cell Lung Cancer | 12/25 | 12/25 | | |
NCT06111274: A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer |
|
|
| Recruiting | 2 | 82 | RoW | Pimicotinib (ABSK021), Gemcitabine, nab-Pacilitaxel, Toripalimab | Abbisko Therapeutics Co, Ltd | Advanced Pancreatic Cancer | 12/25 | 12/26 | | |
ChiCTR-TNRC-08000194: Phase I/IIA study of Icotinib Hydrochloride Tablets in Various Cancer Patients, mainly in Advanced Non-Small Cell Lung Cancer Patients |
|
|
| Completed | 1/2 | 71 | | Oral dosing icotinib tablets, Tid, in continuing 28 days, to assess the safety, tolerance and pharmacokinetics of icotinib. The drug was continued after 28days until documented progressive disease or intolerable toxicity to assess the efficacy of icotinib ;Oral dosing icotinib tablets, Tid, in continuing 28 days, to assess the safety, tolerance and pharmacokinetics of icotinib. The drug was continued after 28days until documented progressive disease or intolerable toxicity to assess the efficacy of icotinib ;Oral dosing icotinib tablets, Tid, in continuing 28 days, to assess the safety, tolerance and pharmacokinetics of icotinib. The drug was continued after 28days until documented progressive disease or intolerable toxicity to assess the efficacy of icotinib ;Oral dosing icotinib tablets, Tid, in continuing 28 days, to assess the safety, tolerance and pharmacokinetics of icotinib. The drug was continued after 28days until documented progressive disease or intolerable toxicity to assess the efficacy of icotinib ;Oral dosing icotinib tablets, Tid, in continuing 28 days, to assess the safety, tolerance and pharmacokinetics of icotinib. The drug was continued after 28days until documented progressive disease or intolerable toxicity to assess the efficacy of icotinib(Among them,14 patients were additional ;Oral dosing icotinib tablets, Tid, in continuing 28 days, to assess the safety, tolerance and pharmacokinetics of icotinib. The drug was continued after 28days until documented progressive disease or intolerable toxicity to assess the efficacy of icotinib(Among them,17 patients were additional | The First Affiliated Hospital, College of Medicine, Zhejiang University; Zhejiang Beta Pharma Inc., Zhejiang Beta Pharma Inc. | various cancer patients, mainly in advanced non-small cell lung cancer patients | | | | |
ChiCTR-PPC-15006771: Clinical study of icotinib combined with radiotherapy in the treatment of EGFR mutation in stage III lung adenocarcinoma |
|
|
| Recruiting | 1/2 | 100 | | icotinib ;PP | Department of Radiation Oncology, Chinese PLA General Hospital; Chinese PLA General Hospital, self-financing | Lung cancer | | | | |
ChiCTR2100044216: A patient with advanced non-small cell lung cancer with positive epidermal growth factor receptor (EGFR) gene sensitive mutations and brain metastases was used as a test subject to evaluate the tolerance and efficacy of ametinib combined with icotinib: single arm study |
|
|
| Recruiting | 1/2 | 46 | | Ametinib 55 mg each time (once a day) and icotinib 125 mg each time (3 times a day) ;Ametinib 110 mg each time (1 time a day) and Icotinib 125 mg each time (3 times a day) ;ametinib at a dose of 55 or 110 mg (once a day) and icotinib at a dose of 125 mg (3 times a day) | West China Hospital, Sichuan University; HANSON PHARMA, HANSON PHARMA | Non-small cell lung cancer | | | | |
